Follows on Orphan Drug Status Granted by FDA Last Year, as Company Initiates Clinical Trial for Stargardt’s Disease MARLBOROUGH, Mass….
Patients for Phase 1/2 Trials Enrolled at UCLA MARLBOROUGH, Mass. – June 16, 2011 – Advanced Cell Technology, Inc. (“ACT”;…
Institutional Review Board (IRB) Approval for Phase I/II Clinical Trial for Dry AMD from Primary Teaching Hospital for Harvard Medical…
MARLBOROUGH, Mass. — March 24, 2014 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of…
Worcester, MA – Advanced Cell Technology, Inc. (OTC Bulletin Board: ACTC.OB) announced today that it has closed a private placement…
FDA Lifts Clinical Hold; Company to Commence a Phase I/II Clinical Trial at Multiple Centers MARLBOROUGH, MA – November 22,…
MARLBOROUGH, Mass.– Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, reported today that…
Worcester, MA, – Advanced Cell Technology, Inc. (ACT) today announced that it has successfully developed a method for producing primitive…
Approach Maintains Developmental Potential of Embryo Worcester, MA – Advanced Cell Technology, Inc (OTC Bulletin Board: ACTC.OB) reported today the…
MARLBOROUGH, Mass. — Jan. 5, 2012 – Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative…